Coined the "most social Asha yet," Nokia's (NYSE: NOK ) latest Wi-Fi-compatible Asha 210 phone includes the mobile industry's first WhatsApp button, the company announced today. In addition to the dedicated WhatsApp feature, the device is available with either single or dual SIM variants, a QWERTY keyboard, and a pre-loaded YouTube launcher.
It comes equipped with a 2MP camera and built-in voice function to help users center images, including self-portraits. Timo Toikkanen, Nokia's executive vice president for mobile phones, said, "The Nokia Asha 210 really stands out giving super-social consumers new ways to express their personalities through design, colour and innovations like the world's first WhatsApp button." The phone also includes ready access to Facebook and Twitter.
The Asha 210�will be introduced in emerging markets including Africa, the Middle East, and parts of Europe. Nokia estimates the retail price will be $72, and it should begin shipping in the second quarter of 2013.
Hot Consumer Service Stocks To Watch For 2015: Galena Biopharma Inc (GALE)
Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). On January 19, 2012, the Company initiated enrollment in its Phase 3 PRESENT clinical trial for NeuVax (E75 peptide plus GM-CSF) vaccine in low-to-intermediate HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence (Clinicaltrials.gov identifier NCT01479244). The Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment study is a randomized, multicenter, multinational clinical trial that will enroll approximately 700 breast cancer patients. The Company�� Phase 2 trial of NeuVax achieved its primary endpoint of disease-free survival (DFS). On April 13, 2011, the Company completed its acquisition of Apthera, Inc.,(Apthera).
The Company focuses to start a Phase 2 trial comparing NeuVax in combination with trastuzumab (Herceptin) versus trastuzumab, alone, in a 300-patient, randomized study in the adjuvant breast cancer setting. The Company's second product candidate, Folate Binding Protein-E39 (FBP), is a vaccine, consisting of the peptides E39 and J65, aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. On February 14, 2012, the Company announced the initiation of a Phase 1/2 clinical trial in two gynecological cancers: ovarian and endometrial adenocarcinomas. Folate binding protein has ! very limited tissue distribution and expression in non-malignant tissue and is over-expressed in more than 90% of ovarian and endometrial cancers, as well as in 20% to 50% of breast, lung, colorectal and renal cell carcinomas.
In April 2011, the Company acquired Apthera Inc and its NeuVax product candidate. The Company focuses on developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide, the advanced of which is NeuVax, which is targeted at preventing the recurrence of breast cancer. NeuVax has had positive Phase 1/2 clinical trial results for the prevention of breast cancer recurrence in patients who have had breast cancer and received the standard of care treatment (surgery, chemotherapy, radiotherapy and hormonal therapy as indicated). The Company had also initiated its Phase 3 PRESENT clinical trial of NeuVax for the prevention of breast cancer recurrence in early-stage low-to-intermediate HER2 breast cancer patients. NeuVax directs killer T-cells to target and destroy cancer cells that express HER2/neu, a protein associated with epithelial tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers. NeuVax is comprised of a HER2/neu-derived peptide called E75. E75 is a nine-amino acid sequence that is immunogenic (produces an immune response) and GM-CSF is a commercially available protein that acts to stimulate and activate components of the immune system such as macrophages and dendritic cells.
The Company also develops novel applications for NeuVax based on preclinical studies and phases 2 clinical trials which suggest that combining NeuVax and trastuzumab (Herceptin; Genentech/Roche) can increase antigen presentation by tumor cells by promoting receptor internalization and subsequent proteosomal degradation of the HER2 protein. The Company also is pursuing additional therapeutic indications for NeuVax that are in Phase 1/2 clinical trials. RXI-109, is a dermal anti-scarring therapy that targets! connecti! ve tissue growth factor (CTGF) and that may inhibit connective tissue formation in human fibrotic disease.
The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc., GlaxoSmithKline plc, Renovo Group plc, CoDa Therapeutics, Inc., Sirnaomics, Inc., FirstString Research, Inc., Merz Pharmaceuticals, LLC, Capstone Therapeutics, Halscion, Inc., Garnet Bio Therapeutics, Inc., AkPharma Inc., Promedior, Inc., Kissei Pharmaceutical Co., Ltd., Eyegene, Derma Sciences, Inc., Healthpoint Biotherapeutics, Pharmaxon, Excaliard Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere Therapeutics, Inc., Benitec Limited, OPKO Health, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics Inc. and Santaris.
Advisors' Opinion:- [By James E. Brumley]
The last two weeks have been absolutely fantastic ones for Galena Biopharma Inc. (NASDAQ:GALE). Shares have soared from $2.37 to the current price of $3.32 - a 40% pop - rewarding investors who had been patiently waiting through late October for the runup to take hold. Congratulations if that's you. But, if that was you, then now might be a great time to take the money and run with the trade, as GALE looks poised to make a sizeable pullback. More on that in a moment.
Top 5 Shipping Stocks To Invest In Right Now: Hospira Inc (HSP)
Hospira, Inc. (Hospira), incorporated on September 16, 2003, is a provider of injectable drugs and infusion technologies. Hospira's portfolio includes generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management products. Hospira's portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. Hospira conducts operations worldwide and is managed in three reportable segments: Americas; Europe, Middle East and Africa (EMEA), and Asia Pacific (APAC). The Americas segment includes the United States, Canada and Latin America; the EMEA segment includes Europe, the Middle East and Africa, and the APAC segment includes Asia, Japan, Australia and New Zealand. In all segments, Hospira sells a line of products, including specialty injectable and other pharmaceuticals and medication management products.
Specialty Injectable Pharmaceuticals
Hospira's specialty injectable pharmaceutical products consist of generic injectable pharmaceuticals. The other drugs' therapeutic areas include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, and other areas. All of Hospira's generic injectable pharmaceuticals in the United States include unit-of-use bar-code labels that can be used to support medication delivery. Hospira primarily procures the active pharmaceutical ingredients in these products from third-party suppliers. During the year ended December 31, 2011, Hospira portfolio included 87 injectable drug launches consisting of 13 compounds. Among these launches included, in the United States, docetaxel (an oncolytic drug used to treat a variety of cancers), topotecan (an oncolytic drug used for the treatment of small cell lung cancer) and imipenem-cilastatin (a beta-lactam antibiotic). Hospira also launched a solution formulation of gemcitabine (an oncolytic drug used to treat a variety of cancers), which augmented Hospira's portfolio of gemcitabin! e products. New-to-country launches in EMEA in 2011, included topotecan, meropenem, gemcitabine, imipenem-cilastatin, remifentanil, docetaxel and levofloxacin. New-to-country launches in APAC in 2011, included docetaxel, piperacillin tazobactam, oxaliplatin, meropenem and gemcitabine. Hospira's specialty injectable pharmaceutical products also include Precedex (dexmedetomidine HCl), a sedative. Precedex is licensed to Hospira by Orion Corporation in the Americas and APAC segments, and in the Middle East and Africa.
Hospira sells and markets Precedex for use in non-intubated patients requiring sedation, as well as intubated and mechanically ventilated patients. Hospira's specialty injectable pharmaceuticals also include biologic products, which are molecules derived from cells that are demonstrated to be similar to an approved originator product. Hospira's biosimilar, Retacrit, was available in 20 EMEA countries during 2011. Its second biosimilar, Nivestim, was launched during the year ended December 31, 2010, and was available in 21 countries, including Australia, where the biosimilar filgrastim product was launched in 2011. Hospira's drug delivery formats include offerings in ampules and flip-top vials, which clinicians can use with standard syringes. Hospira's drug delivery options include Carpuject and iSecure prefilled syringes, AnsyrTM prefilled needleless emergency syringe systems, First Choice ready-to-use premix and the ADD-Vantage system for preparing drug solutions from prepackaged drug powders or concentrates.
Other Pharmaceuticals
Hospira's other pharmaceuticals primarily consist of intravenous (I.V.) solutions, nutritionals and contract manufacturing services. Hospira offers infusion therapy solutions and related supplies that include I.V. solutions for general use, I.V. nutrition products, and solutions for the washing and cleansing of wounds or surgical sites. All of Hospira's injectable I.V. solutions in the United States include unit-of-use bar-c! ode label! s that can be used to support medication management efforts. Hospira also offers infusion therapy solutions in its VisIV non-PVC, non-DEHP I.V. container, an I.V. bag. Hospira's contract manufacturing services are offered through its One2One services group, which provides formulation development, filling and finishing of injectable and oral drugs worldwide. Hospira works with its pharmaceutical and biotechnology customers to develop injectable forms of their drugs, and Hospira fills and finishes those and other drugs into containers and packaging selected by the customer. The customer then sells the finished products under its own label. Hospira's One2One manufacturing services group generally does not manufacture active pharmaceutical ingredients, but offers a range of filling and finishing services in a variety of delivery systems.
Medication Management
Medication management products include electronic drug delivery pumps, safety software and disposable administration sets dedicated to Hospira pumps. These sets are used to deliver I.V. fluids and medications. Hospira also offers software maintenance agreements and other service offerings. Hospira's electronic drug delivery pumps include Hospira's general infusion system, Symbiq; the Plum A+ line of infusion pumps; Hospira's patient-controlled analgesia device, LifeCare PCA; the GemStar ambulatory infusion pump; and the Plum XLD infusion pump. Hospira offers the Hospira MedNet safety software system, which has been designed to enable hospitals to customize intravenous drug dosage limits and track drug delivery to prevent medication errors. The wireless network version of the Hospira MedNet system establishes real-time send-and-receive capability and can interface with select hospital and pharmacy information systems. The Hospira MedNet system is standard in the Symbiq infusion system, and is also available as an additional feature for the Plum A+ line, and LifeCare PCA devices. Hospira also offers safety software with its Ge! mStar pum! p.
Medication management includes TheraDoc, Inc. products, which are module-based clinical surveillance systems that provide patient safety surveillance and clinical decision support. Medication management also includes gravity administration sets and other device products, including needlestick safety products and programs to support Hospira's customers' needlestick prevention initiatives. LifeShield CLAVE and LifeShield MicroCLAVE connectors are one-piece valves that directly connect syringes filled with medications to a patient's I.V. line without the use of needles. ICU Medical's CLAVE connectors are a component of administration sets sold by Hospira to its customers in the United States and select markets outside the United States.
The Company competes with Baxter International Inc., Boehringer Ingelheim, Fresenius Kabi, Pfizer, Sandoz, Sanofi, Teva Pharmaceuticals, B. Braun Melsungen AG, CareFusion, Terumo, Actavis, Intas Pharmaceuticals, Ltd, Medac GmbH, Mylan Inc., Sun Pharmaceutical Industries, Ltd. and Aspen.
Advisors' Opinion:- [By Sean Williams]
And finally, would you be shocked if I said that medical-device and drug maker Hospira (NYSE: HSP ) ended the week on a high following a positive opinion from the CHMP on its biosimilar drug known as inflectra? The drug, which is targeted at treating rheumatoid arthritis, inflammatory bowel diseases, and plaque psoriasis, is a biosimilar of Johnson & Johnson's�blockbuster Remicade, which generates $6 billion in annual sales. Assuming Hospira can gain approval for inflectra (which appears likely, since the EMA often follows the advice of its panel), it could garner a big chunk of J&J's sales in the EU.
- [By Saumya Vaishampayan]
Hospira Inc. (HSP) �shares gained 7%. The company on Wednesday posted a 58% surge in third-quarter profit as revenue edged up 1.4%, with adjusted profit and sales beating expectations.
- [By Holly LaFon]
A few weaker sectors lagged the broad market advance. The energy, telecommunication services, and utilities groups gained ground but at a slower pace than most other S&P 500 sectors. Hess was a welcome exception in energy. Most of our investments in the lagging sectors moved higher but trailed the broad market. Our most disappointing energy holdings shared a common theme: exposure to the mining industry. As concerns about the pace of global economic growth intensified, particularly in emerging markets like China, our positions in Cliffs Natural Resources, Newmont Mining, and Joy Global were negatively affected. Fortunately, these composed relatively small positions in the portfolio. The Major Portfolio Changes table on page 8 shows the stocks in which we were active buyers and sellers during the first half of the year. We initiated positions in Apple (AAPL), Joy Global (JOY), Hospira (HSP), and Western Union (WU), all of which had stumbled in the eyes of investors, resulting in sharply falling share prices before we decided to invest in them. Consequently, the companies' stock valuations became more attractive to us. We normally favor companies whose share prices have declined because of cyclical worries, sector concerns, or company-specific issues. When a stock falls in value, its price/earnings ratio usually declines while its dividend yield increases, characteristics we look for as value investors. The strategy can be rewarding as long as the company's fundamentals are still sound.
- [By Sean Williams]
Drug developer Hospira (NYSE: HSP ) also had a notably impressive day, advancing 6% after receiving a positive opinion on inflectra in Europe. Designed to treat rheumatoid arthritis, inflammatory bowel disease, and plaque psoriasis, inflectra, a biosimilar of Johnson & Johnson's�Remicade, received a positive opinion from the Committee for Medicinal Products for Human Use, meaning it would recommend the European Medicines Agency to approve the drug. This could be a key win for Hospira, because J&J's Remicade was responsible for roughly $6 billion in annual revenue, and could be a huge bottom-line boost for Hospira.
Top 5 Shipping Stocks To Invest In Right Now: Charles River Laboratories International Inc. (CRL)
Charles River Laboratories International, Inc. provides research models and laboratory animal support expertise to help its global partners advance their research and drug development efforts. The company offers a portfolio of services to support discovery and imaging, preclinical and early-phase clinical studies, and biopharmaceutical and endotoxin products and services for manufacturing and quality control. Its portfolio spans the entire research and drug development process, from IND consultation to discovery through market approval, allowing customized approaches to support both single-study or broad-based programs. Charles River Laboratories International serves pharmaceutical and biotechnology companies, as well as government agencies, hospitals, and academic institutions. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Advisors' Opinion:- [By Damian Illia]
Based in Valencia, Calif., and founded in 1991, MannKind Corporation (MNKD) is a development stage biopharmaceutical company. It is engaged in the discovery, development and commercialization of therapeutic products for diseases like diabetes. The company's lead and only late stage pipeline candidate for this year is Afrezza, an inhalation powder which is an ultra insulin therapy for the treatment of adults with type 1 or type 2 diabetes to control their hyperglycemia. Currently, it is in late-stage clinical trials and a final decision from the U.S. regulatory body is expected by April 15, 2014. There is great concern revolving around this decision, as MannKind has already received two complete response letters (CRL) for Afrezza from the FDA, and it was requested to conduct two phase III trials with the next-generation inhaler. Further delay in approval or another setback related to this candidate could be a great danger for the company. Over and probably excessive dependence on Afrezza ���s the company discontinued any other reasearch in other candidates ���s something to worry about. The company has generated no revenue last year round and its shares have experienced a total annual loss of $0.64 so far.
Top 5 Shipping Stocks To Invest In Right Now: Canterbury Park Holding Corporation(CPHC)
Canterbury Park Holding Corporation conducts pari-mutuel wagering operations and hosts unbanked card games at its Canterbury Park racetrack and card room facility in Shakopee, Minnesota. The company operates in three segments: Horse Racing, Card Room, and Concessions. The Horse Racing segment operates year-round pari-mutuel wagering on simulcast horse races, and live thoroughbred and quarter horse races held on a seasonal basis. The Card Room segment offers unbanked card games, which include poker and casino games. The Concessions segment provides food and beverage services for simulcast and live racing, and the card room, as well as for the special events. The company also offers facilities for special events, such as snowmobile races, arts and crafts shows, trade shows, concerts, fundraisers, automobile shows and competitions, vehicle and boat storage, and private parties. In addition, it provides advertising signage space; leases excess parking lot space for various aut omotive activities and vehicle storage; and sells various daily pari-mutuel publications. Canterbury Park Holding Corporation was founded in 1994 and is based in Shakopee, Minnesota.
Advisors' Opinion:- [By Monica Wolfe]
Lastly, Gabelli increased his position in Canterbury Park Holding (CPHC). Gabelli upped his stake 3.18% by purchasing a total of 13,824 shares. He bought these shares at an average price of $11.11 per share, and since then the price per share is up about 3%. Gabelli now holds 447,944 shares, representing 10.74% of the company�� shares outstanding.
No comments:
Post a Comment